Pharmacological targeting of the transcription factor NRf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism

1. Jazwa, A.
2. Rojo, A.I.
3. Innamorato, N.G.
4. Hesse, M.
5. Fernández-Ruiz, J.
6. Cuadrado, A.